Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.